Pfizer and Sangamo sign haemophilia research collaboration

Amy Schofield 11 May 2017

Pfizer has entered into an exclusive license agreement with Sangamo Therapeutics which will see the companies collaborating on a new treatment for haemophilia A.

The companies will work together on the development and commercialisation of a number of gene therapy programmes for haemophilia A, including one of Sangamo's four lead product candidates, SB-525, which Sangamo expects to enter the clinic this quarter.

SB-525 has been granted orphan drug designation by the US Food and Drug Administration and has the potential to be a best-in-class therapy.

Sangamo will receive an upfront payment from Pfizer of $70 million and will be responsible for conducting the SB-525 phase I/II clinical study. It will also assume responsibility for some manufacturing activities.

Pfizer will take operational and financial responsibility for all subsequent research, development, manufacturing and commercialisation activities for the candidate and additional products.

Sangamo could be eligible to receive milestone payments of up to $475 million. 

Dr Mikael Dolsten, president of worldwide research and development at Pfizer, said: "We look forward to working together to advance this potentially transformative treatment for patients living with haemophilia A." 

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.